We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read moreQuality Assessment and Minimizing Racemization, Precipitation, and Radical-Induced Side Reactions by TBEC/Oxyma Couplings in an Environmentally Sensible Solvent
23 Jun 2023 - Elevating 1-tert-Butyl-3-ethylcarbodiimide (TBEC) as a Reagent for Sustainable Peptide Synthesis: Quality Assessment and Minimizing Racemization, Precipitation, and Radical-Induced Side Reactions by TBEC/Oxyma Couplings in an Environmentally […]
Read moreTrending topics at PolyPeptide
1 Jun 2023 - We are proud to share some of the recent recorded presentations from our experts at TIDES USA 2023: “Raw material control strategy” Eran Benjamin, Global Director […]
Read morePolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs
9 May 2023 - Baar (Switzerland) and Düsseldorf (Germany), 9 May 2023 – PolyPeptide, a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs), and Numaferm, a German […]
Read morePolyPeptide launches new “Innovation Lab”
8 May 2023 - Strasbourg, France, 8 May 2023 – To support its strategic ambitions, PolyPeptide relocated and expanded its Innovation Lab in Strasbourg. The Group’s central innovation team under […]
Read moreAssessment of Sulfur Impurities in GMP-Grade Diisopropylcarbodiimide and Their Impact on Coupling Reagent-Induced Side Reactions in Peptide Synthesis
4 May 2023 - Jan Pawlas and Jon H. Rasmussen Abstract Diisopropylcarbodiimide (DIC) constitutes one of the most widely used coupling reagents for amide bond formation in peptide synthesis. […]
Read morePolyPeptide announces results of the annual General Meeting 2023
12 Apr 2023 - Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), today announced that […]
Read moreGreen Chemistry Articles of Interest to the Pharmaceutical Industry
4 Apr 2023 - Bryan, M. C.; Dalton, C.; Díaz-Rodríguez, A.; Doerfler, J.; Engl, O. D.; Molina, A. G.; Harawa, V.; Kelly, C. B.; Li, W.; Munday, R. H.; Pawlas, […]
Read morePolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
3 Apr 2023 - Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]
Read more